BRIEF-Gilead’S Livdelzi Delivers Statistically Significant Composite ALP Normalization In Phase 3 IDEAL Trial In Primary Biliary Cholangitis

Gilead Sciences, Inc.

Gilead Sciences, Inc.

GILD

0.00

June 2 (Reuters) - Gilead Sciences, Inc GILD.O:

  • GILEAD’S LIVDELZI® (SELADELPAR) DELIVERS STATISTICALLY SIGNIFICANT COMPOSITE ALP NORMALIZATION IN PHASE 3 IDEAL TRIAL IN PRIMARY BILIARY CHOLANGITIS (PBC)

  • GILEAD - NO NEW SAFETY CONCERNS IDENTIFIED FOR SELADELAPR IN IDEAL STUDY

  • GILEAD: 52-WEEK RESULTS DEMONSTRATE HIGH AND SUSTAINED ALP NORMALIZATION AND GENERALLY WELL-TOLERATED SAFETY PROFILE

Source text: ID:nBw7fMpJVa

Further company coverage: GILD.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.